Updated Feb. 17, 2022 - Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV

What’s New

February 17, 2022

Key updates to the guidelines include the following:

Mycobacterium tuberculosis 

• Updated references and rationales.
• Updated drug–drug interactions.
• Recommended short-course, rifamycin-based, latent tuberculosis infection (LTBI) treatment regimens (3HP and 3HR) over longer isoniazid monotherapy.
• Clarified that, for the treatment of drug-resistant tuberculosis, it is possible to use drug regimens with total duration as short as 6 to 12 months total when bedaquiline is part of the regimen instead of the 18 to 20 months total duration suggested by other sources

Link to the document: https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines